Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Catherine S Diefenbach, M.D

ECOG-ACRIN Cancer Research Group

Intervention

Biopsy Procedure(procedure)

Enrollment

146 enrolled

Eligibility

12 years · All sexes

Timeline

2014 – 2026

Study locations (30)

• Children's Hospital of Alabama, Birmingham, Alabama, United States
• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Kingman Regional Medical Center, Kingman, Arizona, United States
• Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
• Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
• CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07275216
  Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
  City of Hope Medical Center
• RECRUITINGPHASE2NCT07209059
  PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
  National Research Center for Hematology, Russia
• RECRUITINGPHASE2NCT06984146
  Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
  National Medical Research Radiological Centre of the Ministry of Health of Russia
• RECRUITINGPHASE2NCT06745076
  Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
  University of Washington
• RECRUITINGPHASE1, PHASE2NCT06642792
  A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
  Akeso
• RECRUITINGPHASE2NCT06377540
  MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
  Masonic Cancer Center, University of Minnesota
• RECRUITINGPHASE2NCT07234487
  Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL
  St. Petersburg State Pavlov Medical University
• RECRUITINGPHASE2NCT06812858
  PD-1 Inhibitors Maintenance for cHL Post-autoHCT
  St. Petersburg State Pavlov Medical University

See all trials for Classic Hodgkin lymphoma →